Business Wire

LR Health & Beauty Takes Fragrance Segment to a New Level and Launches Two New Collections

22.9.2025 14:42:00 CEST | Business Wire | Press Release

Share

Choosing a favourite perfume is a highly personal decision for many people. Because a fragrance is more than just a scent. It expresses your style, your attitude to life and stirs up emotions – in yourself and in the people around you. Since its foundation in 1985, LR Health & Beauty has been aware of the importance and potential of a successful fragrance range. This is because one of the key advantages of direct sales is the personal advice provided to customers by independent LR sales partners.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250922789464/en/

LR sets new standards in the fragrance sector with the launch of two new fragrance collections

"LR has continuously developed the fragrance portfolio based on direct feedback from our sales partners, our wealth of experience and the latest scientific findings. To mark the 40th anniversary of LR, we have now added the crowning glory to this segment," says Jörg Körfer, CEO of the LR Group.

Scientifically proven effect: 18 fragrances for 18 different moods

LR‘s new fragrance line LR MOOD INFUSION, comprises eleven women's and seven men’s fragrances, and harnesses the power of mood technology to intensify emotions and enhance personal moods. "Fragrance mood technology is a patented neuroscientific study that proves that Mood Infusion activates neural markers and specifically influences emotions," states Dr Christian Rößle, Vice President Research, Development & Quality at LR. Each EDP in this collection has a unique effect – from refreshing and calming to stimulating. "During the development phase we placed great emphasis on improving the formulas to reflect the fragrances of our previous top-selling perfumes," says Rößle, highlighting that LR has taken the preferences of its loyal regular customers into account.

In addition to an intense fragrance experience, the packaging of the new line also impresses with its modern design featuring individual colours, a magnetic cap and, last but not least, a high-quality spray head for excellent fragrance diffusion.

Highest quality and intensity – combined in an ultimate luxury line

Glamour, prestige, strength and sensuality are embodied in the four fragrances of the LR ICONIC ELIXIRS collection. The two women's and two men's fragrances envelop the senses like liquid gold which give the wearer a fabulous glow. Carefully selected ingredients such as Egyptian jasmine and Brazilian tonka bean guarantee the unique intensity of these exquisite high-end perfumes. "Our LR ICONIC ELIXIRS line unleashes the magic of extremely rare and valuable essences. For example, 800 kilograms of Egyptian jasmine flowers – one of the most precious flowers in the world – are required to produce 1 kilogram of extract. The result: an expressive and long-lasting fragrance experience with a very special charisma that goes beyond the ordinary," says Rößle. The luxurious packaging rounds off the sumptuous presentation of the four fragrances and perfectly suits the taste of true connoisseurs.

"I am delighted with the reorientation of our fragrance segment. The simplification of the range provides greater clarity, and the improved quality significantly enhances product performance, as clearly demonstrated by an initial pre-test with selected sales partners," states Körfer.

Both collections are "Made in Germany" and were developed in collaboration with renowned fragrance houses.

LR Group

Under the motto “More quality for your life”, the LR Group – headquartered in the town of Ahlen/Westphalia (Germany) – successfully produces and distributes various high-quality nutritional supplements and cosmetic products in 32 countries through its independent LR sales partners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250922789464/en/

Contacts

PR contact:
LR Global Holding GmbH
Almut Kellermeyer
Head of Corporate Communication
Kruppstraße 55
59227 Ahlen
Germany
Phone: +49 (0) 2382 7658-106
email: A.Kellermeyer@LRworld.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye